Approximately 600 times a day, the esophagus ferries whatever is in your mouth down to your stomach. It's usually a one-way ...

PP02.05 Initial Results from RESOLVE, a Phase 1b Dose-Escalation Study of EP-104GI (Extended-Release Fluticasone ...

today announced that the Company will be presenting a poster at the upcoming 20th International Symposium on Digestive Endoscopy ("ISDE") World Congress for Esophageal Diseases to be held in ...

In the present study, also signs were improved including lower esophageal sphincter (LES) pressure (from 10 ± 1.58 and, 10.3 ± 1.68 mmHg in the pretreated patients to 16.5 ± 0.6, and 14.1 ± 0. ...

First described nearly 20 years ago, eosinophilic esophagitis (EoE) is an inflammatory disease of the esophagus characterized by eosinophilic infiltration of the esophageal epithelium. Over 50% of ...

Oncologists are perturbed by the increase in early-onset tumors and the potential role of lifestyle, though this may not ...

Eupraxia Pharmaceuticals Inc., a clinical-stage biotechnology company leveraging its proprietary DiffuSphere technology to optimize drug delivery for applications with significant unmet need, ...

ADCs, particularly Enhertu and datopotamab deruxtecan, are showing promising results. See why I rate the stock a buy.